The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 30, 2025
Filed:
Jun. 21, 2021
Juno Therapeutics, Inc., Seattle, WA (US);
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Blythe D. Sather, Seattle, WA (US);
Eric L. Smith, New York, NY (US);
Rupesh Amin, Seattle, WA (US);
Aye Chen, Seattle, WA (US);
Kimberly Harrington, Seattle, WA (US);
Collin Hauskins, Seattle, WA (US);
Erik Hess, Seattle, WA (US);
Cyr De Imus, Seattle, WA (US);
Jon Jones, Seattle, WA (US);
Audrey Olshefsky, Seattle, WA (US);
Stefan Ponko, Seattle, WA (US);
Ruth Salmon, Seattle, WA (US);
Semih Tareen, Seattle, WA (US);
Rebecca Wu, Seattle, WA (US);
Yan Chen, Seattle, WA (US);
Steven M. Shamah, Seattle, WA (US);
Csaba Pazmany, Seattle, WA (US);
Jui Dutta-Simmons, Seattle, WA (US);
Mariana Cota Stirner, Seattle, WA (US);
Melissa Works, Seattle, WA (US);
Juno Therapeutics, Inc., Seattle, WA (US);
Memorial Sloan Kettering Cancer Center, New York, NY (US);
Abstract
Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.